Creon 60000 [USP'U]/1

Pancrelipase, the active ingredient in Creon 60000 [USP'U]/1, is a pancreatic enzyme replacement therapy presented as a 60000 USP units per capsule, delayed-release pellets for oral use. It is used to aid digestion in patients with exocrine pancreatic insufficiency due to conditions such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, or pancreatic resection.

GNH USA supplies Creon 60000 [USP'U]/1 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Creon 60000 [USP'U]/1 is indicated for the treatment of exocrine pancreatic insufficiency, a condition where the pancreas does not produce enough digestive enzymes. This can occur due to various conditions, including:

- Cystic fibrosis: Helps improve digestion and nutrient absorption in patients with cystic fibrosis. - Chronic pancreatitis: Aids in the digestion of fats, proteins, and carbohydrates in patients with chronic pancreatitis. - Pancreatic cancer: Supports digestion in patients who have undergone pancreatic resection or have pancreatic cancer. - Pancreatectomy: Assists in the digestion process for patients who have had part or all of their pancreas removed.

Creon 60000 [USP'U]/1 may cause side effects, although not everyone gets them. Common Side Effects: - Abdominal pain - Diarrhea - Nausea - Vomiting - Dizziness - Cough Serious or Rare Side Effects: - Fibrosing colonopathy: A serious condition that affects the colon. - Gastrointestinal obstruction: Blockage in the digestive tract. - Hyperuricemia: High levels of uric acid in the blood. - Pruritus ani: Itching around the anal area. - Urticaria: Hives or skin rash.

Creon 60000 [USP'U]/1 should be used with caution and under medical supervision. Important precautions include: - Do not crush, chew, or retain in the mouth: Ensure the capsule is swallowed whole to avoid irritation of the oral mucosa. - Do not exceed recommended dosage: Exceeding 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day may increase the risk of side effects. - Monitor for fibrosing colonopathy: Regular monitoring is essential to detect any signs of this serious condition. - Avoid inhalation of powder: Care should be taken to avoid inhaling the powder when opening the capsule. - Store below 25°C: Keep in the original pack, protect from moisture.

Creon 60000 [USP'U]/1 may interact with other medications. Major Interactions (Avoid): - Antacids: May decrease the effectiveness of Creon by altering stomach pH. - H2-receptor antagonists: Can reduce the activity of pancreatic enzymes. Moderate Interactions (Monitor Closely): - Iron supplements: May reduce the absorption of iron. - Folic acid supplements: May interfere with the absorption of folic acid. - Other digestive enzymes: Concurrent use may lead to excessive enzyme activity.